BR112014032264A2 - composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo - Google Patents

composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo

Info

Publication number
BR112014032264A2
BR112014032264A2 BR112014032264A BR112014032264A BR112014032264A2 BR 112014032264 A2 BR112014032264 A2 BR 112014032264A2 BR 112014032264 A BR112014032264 A BR 112014032264A BR 112014032264 A BR112014032264 A BR 112014032264A BR 112014032264 A2 BR112014032264 A2 BR 112014032264A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
composition
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BR112014032264A
Other languages
English (en)
Other versions
BR112014032264A8 (pt
Inventor
Ji Yeon Kim
Won Hhe Suh
Original Assignee
Univ Ajou Ind Academic Coop Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ajou Ind Academic Coop Found filed Critical Univ Ajou Ind Academic Coop Found
Publication of BR112014032264A2 publication Critical patent/BR112014032264A2/pt
Publication of BR112014032264A8 publication Critical patent/BR112014032264A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014032264A 2012-06-18 2013-06-10 Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo BR112014032264A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120065193A KR101386697B1 (ko) 2012-06-18 2012-06-18 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
PCT/KR2013/005068 WO2013191401A1 (ko) 2012-06-18 2013-06-10 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 질환의 치료 또는 예방용 조성물

Publications (2)

Publication Number Publication Date
BR112014032264A2 true BR112014032264A2 (pt) 2017-06-27
BR112014032264A8 BR112014032264A8 (pt) 2022-03-03

Family

ID=49768959

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032264A BR112014032264A8 (pt) 2012-06-18 2013-06-10 Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo

Country Status (11)

Country Link
US (1) US9511068B2 (pt)
EP (1) EP2862573B1 (pt)
JP (1) JP6030234B2 (pt)
KR (1) KR101386697B1 (pt)
CN (2) CN104582704A (pt)
BR (1) BR112014032264A8 (pt)
CA (1) CA2876926C (pt)
ES (1) ES2668908T3 (pt)
MX (1) MX365021B (pt)
RU (2) RU2014151382A (pt)
WO (1) WO2013191401A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101498973B1 (ko) 2013-11-21 2015-03-05 현대모비스(주) 차량용 주차 지원 시스템 및 방법
GB201401005D0 (en) * 2014-01-21 2014-03-05 Ucl Business Plc Inhibitor
KR101778004B1 (ko) * 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0201882D0 (en) 2002-01-28 2002-03-13 Novartis Ag Organic compounds
EP1494699A4 (en) 2002-04-11 2009-07-22 Childrens Medical Center METHOD FOR INHIBITING VASCULAR HYPERPERMEABILITY
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EA010485B1 (ru) * 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
CN1934255B (zh) 2003-08-27 2012-07-11 奥普索特克公司 用于治疗眼新血管疾病的组合治疗
GB0421438D0 (en) * 2004-09-27 2004-10-27 Astrazeneca Ab Combination therapy
PT1750713E (pt) * 2004-06-04 2013-01-25 Bioniche Life Sciences Inc Utilização de imatinib para tratar distúrbios e infeções virais do fígado
EP1804802A2 (en) 2004-09-27 2007-07-11 AstraZeneca AB Combination comprising zd6474 and an imatinib
JP2008514576A (ja) * 2004-09-27 2008-05-08 アストラゼネカ アクチボラグ Azd2171およびイマチニブを含む癌組合せ療法
CN101035536A (zh) * 2004-10-08 2007-09-12 诺瓦提斯公司 有机化合物的组合
PL1893213T3 (pl) 2005-06-03 2010-08-31 Novartis Ag Kombinacja związków pirymidyloaminobenzamidowych i imatinibu do leczenia lub profilaktyki chorób proliferacyjnych
US20080003219A1 (en) * 2005-09-26 2008-01-03 Minu, L.L.C. Delivery of an ocular agent
MX2009004861A (es) 2006-11-09 2009-05-21 Abbott Gmbh & Co Kg Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
SI2305263T1 (sl) 2007-06-07 2012-10-30 Novartis Ag Stabilizirane amorfne oblike imatinib mezilata
TW201102068A (en) * 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
KR101138840B1 (ko) 2009-12-28 2012-05-10 주식회사 셀트리온화학연구소 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물

Also Published As

Publication number Publication date
MX2014015785A (es) 2015-06-10
JP2015520226A (ja) 2015-07-16
RU2018128737A3 (pt) 2019-03-14
BR112014032264A8 (pt) 2022-03-03
KR20130141998A (ko) 2013-12-27
JP6030234B2 (ja) 2016-11-24
US9511068B2 (en) 2016-12-06
EP2862573B1 (en) 2018-03-07
CN107496426A (zh) 2017-12-22
MX365021B (es) 2019-05-20
EP2862573A1 (en) 2015-04-22
ES2668908T3 (es) 2018-05-23
CA2876926C (en) 2017-04-04
RU2014151382A (ru) 2016-08-10
CA2876926A1 (en) 2013-12-27
EP2862573A4 (en) 2016-01-27
RU2018128737A (ru) 2019-03-14
US20150320750A1 (en) 2015-11-12
KR101386697B1 (ko) 2014-04-18
CN104582704A (zh) 2015-04-29
WO2013191401A1 (ko) 2013-12-27

Similar Documents

Publication Publication Date Title
BR112015003376A8 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
WO2013012915A8 (en) Heterocyclic compounds and uses thereof
CO7061081A2 (es) Derivados macrocíclicos para el tratamiento de enfermedades
BR112014028395A2 (pt) derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer
EP2671586A4 (en) PHARMACOTHERAPY FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
LTPA2020511I1 (lt) Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
GT201400161A (es) Fenilimidazopirazoles sustituidos y su uso
CL2014003123A1 (es) 5-amino [1,4], tiazinas como inhibidores de bace1; uso del compuesto contra la enfermedad de alzheimer.
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
EP2990040A4 (en) Therapeutic agent for eyeground disease
PL3031465T3 (pl) Kompozycja farmaceutyczna do sprzyjania tworzeniu tkanki kostnej, zawierająca jako składnik czynny wyciąg z liści stauntonia hexaphylla
HK1207579A1 (en) Composition for preventing or treating heart disease
EP3311817A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF EYES DISEASES WITH IMATINIB AS AN ACTIVE SUBSTANCE
EP2799082A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORAL DISEASES OR ASTHMA CONTAINING A STOREM STEREMIA OVALIFOLIA EXTRACT OR A FRACTION OF IT AS AN ACTIVE SUBSTANCE
BR112014032264A2 (pt) composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo
EP2910246A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER WITH ENOBLOCK AS AN ACTIVE SUBSTANCE
EP2873419A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING AZATHIOPRIN AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF BRAIN TUMORS OR TUMODAL RESISTANT GLIOBLASTOMES
EP2870971A4 (en) MEDICAMENT FOR THE PREVENTION / TREATMENT OF AN OCULAR DISEASE
PT2938328T (pt) Fármaco monolítico para a libertação modificada de uma combinação de princípios ativos
EP2789337A4 (en) PHARMACEUTICAL COMPOSITION WITH BICYCLIC PYRIDINOL DERIVATIVES FOR PREVENTING OR TREATING ANTICIPATED ANALYSIS OF ANGIOGENESIS
LT2704698T (lt) Vaisto forma, skirta aktyvių ingredientų kontroliuojamam atpalaidavimui
IL238071B (en) Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]